Skip to main content
Erschienen in: Cancer Causes & Control 3/2021

04.01.2021 | Original Paper

Adherence to annual lung cancer screening with low-dose CT scan in a diverse population

verfasst von: Cherie P. Erkmen, Farouk Dako, Ryan Moore, Chandra Dass, Mark G. Weiner, Larry R. Kaiser, Grace X. Ma

Erschienen in: Cancer Causes & Control | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Our aim was to develop a novel approach for lung cancer screening among a diverse population that integrates the Centers for Medicare and Medicaid Services (CMS) recommended components including shared decision making (SDM), low-dose CT (LDCT), reporting of results in a standardized format, smoking cessation, and arrangement of follow-up care.

Methods

Between October of 2015 and March of 2018, we enrolled patients, gathered data on demographics, delivery of SDM, reporting of LDCT results using Lung-RADS, discussion of results, and smoking cessation counseling. We measured adherence to follow-up care, cancer diagnosis, cancer treatment, and smoking cessation at 2 years after initial LDCT.

Results

We enrolled 505 patients who were 57% African American, 30% Caucasian, 13% Hispanic, < 1% Asian, and 61% were active smokers. All participants participated in SDM, 88.1% used a decision aid, and 96.1% proceeded with LDCT. Of 496 completing LDCT, all received a discussion about results and follow-up recommendations. Overall, 12.9% had Lung-RADS 3 or 4, and 3.2% were diagnosed with lung cancer resulting in a false-positive rate of 10.7%. All 48 patients with positive screens but no cancer diagnosis adhered to follow-up care at 1 year, but only 35.4% adhered to recommended follow-up care at 2 years. The annual follow-up for patients with negative lung cancer screening results (Lung-RADS 1 and 2) was only 23.7% after one year and 2.8% after 2 years. All active smokers received smoking cessation counseling, but only 11% quit smoking.

Conclusion

The findings show that an integrated lung cancer screening program can be safely implemented in a diverse population, but adherence to annual screening is poor.
Literatur
1.
2.
Zurück zum Zitat Aberle DR, Adams AM et al (2012) National Lung Screening Trial Research Team, Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365(5):395–409 Aberle DR, Adams AM et al (2012) National Lung Screening Trial Research Team, Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365(5):395–409
3.
6.
Zurück zum Zitat Doria-Rose VP, White MC, Klabunde CN et al (2012) Use of lung cancer screening tests in the United States: results from the 2010 National Health Interview Survey. Cancer Epidemiol Biomark Prev 21(7):1049–1059CrossRef Doria-Rose VP, White MC, Klabunde CN et al (2012) Use of lung cancer screening tests in the United States: results from the 2010 National Health Interview Survey. Cancer Epidemiol Biomark Prev 21(7):1049–1059CrossRef
7.
Zurück zum Zitat Japuntich SJ, Krieger NH, Salvas AL, Carey MP (2018) Racial disparities in lung cancer screening: an exploratory investigation. J Natl Med Assoc 110(5):424–427CrossRefPubMed Japuntich SJ, Krieger NH, Salvas AL, Carey MP (2018) Racial disparities in lung cancer screening: an exploratory investigation. J Natl Med Assoc 110(5):424–427CrossRefPubMed
8.
Zurück zum Zitat Carter-Harris L, Slaven JE Jr, Monahan PO, Shedd-Steele R, Hanna N, Rawl SM (2018) Understanding lung cancer screening behavior: racial, gender, and geographic differences among Indiana long-term smokers. Prev Med Rep 10:49–54CrossRefPubMedPubMedCentral Carter-Harris L, Slaven JE Jr, Monahan PO, Shedd-Steele R, Hanna N, Rawl SM (2018) Understanding lung cancer screening behavior: racial, gender, and geographic differences among Indiana long-term smokers. Prev Med Rep 10:49–54CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Tangka FK, Subramanian S, Mobley LR et al (2017) Racial and ethnic disparities among state Medicaid programs for breast cancer screening. Prev Med 102:59–64CrossRefPubMedPubMedCentral Tangka FK, Subramanian S, Mobley LR et al (2017) Racial and ethnic disparities among state Medicaid programs for breast cancer screening. Prev Med 102:59–64CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Tanner NT, Gebregziabher M, Hughes Halbert C, Payne E, Egede LE, Silvestri GA (2015) Racial differences in outcomes within the national lung screening trial. Implications for widespread implementation. Am J Respir Crit Care Med 192(2):200–208CrossRefPubMed Tanner NT, Gebregziabher M, Hughes Halbert C, Payne E, Egede LE, Silvestri GA (2015) Racial differences in outcomes within the national lung screening trial. Implications for widespread implementation. Am J Respir Crit Care Med 192(2):200–208CrossRefPubMed
11.
Zurück zum Zitat Wools A, Dapper EA, Leeuw JRJ (2015) Colorectal cancer screening participation: a systematic review. Eur J Public Health 26(1):158–168CrossRefPubMed Wools A, Dapper EA, Leeuw JRJ (2015) Colorectal cancer screening participation: a systematic review. Eur J Public Health 26(1):158–168CrossRefPubMed
13.
Zurück zum Zitat Lau YK, Caverly TJ, Cao P et al (2015) Evaluation of a personalized, web-based decision aid for lung cancer screening. Am J Prev Med 49(6):e125-129CrossRefPubMedPubMedCentral Lau YK, Caverly TJ, Cao P et al (2015) Evaluation of a personalized, web-based decision aid for lung cancer screening. Am J Prev Med 49(6):e125-129CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Kazerooni EA, Austin JHM, Black WC et al (2014) ACR–STR practice parameter for the performance and reporting of lung cancer screening thoracic computed tomography (CT): 2014 (Resolution 4)*. J Thorac Imaging 29(5):310–316CrossRefPubMed Kazerooni EA, Austin JHM, Black WC et al (2014) ACR–STR practice parameter for the performance and reporting of lung cancer screening thoracic computed tomography (CT): 2014 (Resolution 4)*. J Thorac Imaging 29(5):310–316CrossRefPubMed
16.
Zurück zum Zitat Shaik SS, Doshi D, Bandari SR, Madupu PR, Kulkarni S (2016) Tobacco use cessation and prevention - a review. J Clin Diagn Res 10(5):13–17 Shaik SS, Doshi D, Bandari SR, Madupu PR, Kulkarni S (2016) Tobacco use cessation and prevention - a review. J Clin Diagn Res 10(5):13–17
17.
Zurück zum Zitat Ma J, Ward EM, Smith R, Jemal A (2013) Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer 119(7):1381–1385CrossRefPubMed Ma J, Ward EM, Smith R, Jemal A (2013) Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer 119(7):1381–1385CrossRefPubMed
18.
Zurück zum Zitat Mazzone PJ, Tenenbaum A, Seeley M, Petersen H, Lyon C, Han X, Wang XF (2017) Impact of a lung cancer screening counseling and shared decision-making visit. Chest 151(3):572–578CrossRefPubMed Mazzone PJ, Tenenbaum A, Seeley M, Petersen H, Lyon C, Han X, Wang XF (2017) Impact of a lung cancer screening counseling and shared decision-making visit. Chest 151(3):572–578CrossRefPubMed
19.
Zurück zum Zitat Kinsinger LS, Anderson C, Kim J, Larson M et al (2017) Implementation of lung cancer screening in the Veterans Health Administration. JAMA Intern Med 177(3):399–406CrossRefPubMed Kinsinger LS, Anderson C, Kim J, Larson M et al (2017) Implementation of lung cancer screening in the Veterans Health Administration. JAMA Intern Med 177(3):399–406CrossRefPubMed
20.
Zurück zum Zitat Huo J, Hong YR, Bian J, Guo Y, Wilkie DJ, Mainous AG (2019) Low rates of patient-reported physician-patient discussion about lung cancer screening among current smokers: data from health information national trends survey. Cancer Epidemiol Biomark Prev 28(5):963–973CrossRef Huo J, Hong YR, Bian J, Guo Y, Wilkie DJ, Mainous AG (2019) Low rates of patient-reported physician-patient discussion about lung cancer screening among current smokers: data from health information national trends survey. Cancer Epidemiol Biomark Prev 28(5):963–973CrossRef
21.
Zurück zum Zitat Moolgavkar SH, Holford TR, Levy DT, Kong CY et al (2012) Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975–2000. J Natl Cancer Inst 104(7):541–548CrossRefPubMedPubMedCentral Moolgavkar SH, Holford TR, Levy DT, Kong CY et al (2012) Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975–2000. J Natl Cancer Inst 104(7):541–548CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Villanti AC, Jiang Y, Abrams DB, Pyenson BS (2013) A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PLoS ONE 8(8):e71379CrossRefPubMedPubMedCentral Villanti AC, Jiang Y, Abrams DB, Pyenson BS (2013) A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PLoS ONE 8(8):e71379CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Joseph AM, Rothman AJ, Almirall D et al (2018) Lung cancer screening and smoking cessation clinical trials. SCALE (smoking cessation within the context of lung cancer screening) collaboration. Am J Respir Crit Care Med 197(2):172–182CrossRefPubMedPubMedCentral Joseph AM, Rothman AJ, Almirall D et al (2018) Lung cancer screening and smoking cessation clinical trials. SCALE (smoking cessation within the context of lung cancer screening) collaboration. Am J Respir Crit Care Med 197(2):172–182CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Pinsky PF, Gierada DS, Black W et al (2015) Performance of Lung-RADS in the national lung screening trial: a retrospective assessment. Ann Intern Med 162(7):485–491CrossRefPubMedPubMedCentral Pinsky PF, Gierada DS, Black W et al (2015) Performance of Lung-RADS in the national lung screening trial: a retrospective assessment. Ann Intern Med 162(7):485–491CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Aberle DR (2017) Implementing lung cancer screening: the US experience. Clin Radiol 72(5):401–406CrossRefPubMed Aberle DR (2017) Implementing lung cancer screening: the US experience. Clin Radiol 72(5):401–406CrossRefPubMed
26.
Zurück zum Zitat Muñoz-Largacha JA, Steiling KA, Kathuria H et al (2018) Initial surgical experience following implementation of lung cancer screening at an urban safety net hospital. J Thorac Cardiovasc Surg 155(6):2674–2681CrossRefPubMed Muñoz-Largacha JA, Steiling KA, Kathuria H et al (2018) Initial surgical experience following implementation of lung cancer screening at an urban safety net hospital. J Thorac Cardiovasc Surg 155(6):2674–2681CrossRefPubMed
27.
Zurück zum Zitat Erkmen CP, Mitchell M, Randhawa S et al (2018) An enhanced shared decision making model to address willingness and ability to undergo lung cancer screening and follow-up treatment in minority underserved populations. J Community Health 43(1):27–32CrossRefPubMed Erkmen CP, Mitchell M, Randhawa S et al (2018) An enhanced shared decision making model to address willingness and ability to undergo lung cancer screening and follow-up treatment in minority underserved populations. J Community Health 43(1):27–32CrossRefPubMed
28.
Zurück zum Zitat Alshora S, McKee BJ, Regis SM, Borondy Kitts AK, Bolus CC, McKee AB, French RJ, Flacke S, Wald C (2018) Adherence to radiology recommendations in a clinical CT lung screening program. J Am Coll Radiol 15(2):282–286CrossRefPubMed Alshora S, McKee BJ, Regis SM, Borondy Kitts AK, Bolus CC, McKee AB, French RJ, Flacke S, Wald C (2018) Adherence to radiology recommendations in a clinical CT lung screening program. J Am Coll Radiol 15(2):282–286CrossRefPubMed
29.
Zurück zum Zitat Robbins HA, Berg CD, Cheung LC, Chaturvedi AK, Katki HA (2019) Identification of candidates for longer lung cancer screening intervals following a negative low-dose computed tomography result. J Natl Cancer Inst 111(9):996–999CrossRefPubMedPubMedCentral Robbins HA, Berg CD, Cheung LC, Chaturvedi AK, Katki HA (2019) Identification of candidates for longer lung cancer screening intervals following a negative low-dose computed tomography result. J Natl Cancer Inst 111(9):996–999CrossRefPubMedPubMedCentral
Metadaten
Titel
Adherence to annual lung cancer screening with low-dose CT scan in a diverse population
verfasst von
Cherie P. Erkmen
Farouk Dako
Ryan Moore
Chandra Dass
Mark G. Weiner
Larry R. Kaiser
Grace X. Ma
Publikationsdatum
04.01.2021
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 3/2021
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-020-01383-0

Weitere Artikel der Ausgabe 3/2021

Cancer Causes & Control 3/2021 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.